{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:43:19Z","timestamp":1761396199287,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold>The aim was to study the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cells in adults with B-cell lymphoma.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>From October 2015 to October 2021, we treated five patients with B-cell lymphoma, comprising two with mantle cell lymphoma, one case of Burkitt lymphoma, one case of diffuse large B-cell lymphoma, and one case of chronic lymphocytic leukemia\/small lymphocytic lymphoma. The patients were given the FC regimen 5\u00a0days before the infusion of anti-CD19 CAR T-cells. The median total number of CAR T-cells infusions was 350*10^6 (88*10^6\u2013585*10^6).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>1) Patients who received CAR T-cell induction therapy achieved complete remission (CR) in Case 1 and Case 3 and partial remission (PR) in Case 2. Case 3\u2019s ATM and D13S25 gene deletions were negative 42\u00a0days after CAR T-cell therapy, and molecular biology CR (mCR) and minimal residual disease (MRD) were negative for 5\u00a0years and 6\u00a0months. The patient in Case 3 was cured. 2) Case 4 patient\u2019s TP53 gene mutation became negative 1\u00a0month after CAR T-cell therapy. MRD was negative after CAR T-cell therapy at 41 and 42\u00a0months in Cases 4 and 5, respectively. 3) Case 1\u223cCase 3 patients developed cytokine release syndrome (CRS) without encephalopathy syndrome, accompanied with serious adverse events. CRS can be effectively managed with tocilizumab, etanercept, glucocorticoids, and plasmapheresis.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>Anti-CD19 CAR T-cell therapy is effective in treating relapsed\/refractory B-cell lymphoma, and the side effects of CAR T-cell therapy can be properly managed. CAR T-cell therapy has high efficacy and presented no side effects in the treatment of MRD in B-cell lymphoma (NCT03685786, NCT02456350).<\/jats:p>","DOI":"10.3389\/fgene.2021.815679","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:13:01Z","timestamp":1642662781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenyujing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changru","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 Expression in CAR-T Cells Improves Immune Cell Infiltration and CAR-T Cell Survival in the Tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.158.9.4045","article-title":"Involvement of IL-10 in the Autonomous Growth of EBV-Transformed B Cell Lines","volume":"158","author":"Beatty","year":"1997","journal-title":"J. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s0140-6736(14)61184-3","article-title":"Long-term Outcomes after Stenting versus Endarterectomy for Treatment of Symptomatic Carotid Stenosis: the International Carotid Stenting Study (ICSS) Randomised Trial","volume":"385","author":"Bonati","year":"2015","journal-title":"The Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of Large, Established Tumor Xenografts with Genetically Retargeted Human T Cells Containing CD28 and CD137 Domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3389\/fonc.2020.01460","article-title":"Key Players in the Mutant P53 Team: Small Molecules, Gene Editing, Immunotherapy","volume":"10","author":"Chasov","year":"2020","journal-title":"Front. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/nejmra0708875","article-title":"Monoclonal Antibody Therapy for B-Cell Non-hodgkin's Lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse Large B-Cell Lymphoma: R-CHOP Failure-What to Do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric Antigen Receptors for the Adoptive T Cell Therapy of Hematologic Malignancies","volume":"99","author":"Davila","year":"2014","journal-title":"Int. J. Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.4049\/jimmunol.0904180","article-title":"Analysis of Complex Biomarkers for Human Immune-Mediated Disorders Based on Cytokine Responsiveness of Peripheral Blood Cells","volume":"184","author":"Davis","year":"2010","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40259-017-0246-1","article-title":"GP2015: An Etanercept Biosimilar","volume":"31","author":"Deeks","year":"2017","journal-title":"BIODRUGS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and Development of Therapies Using Chimeric Antigen Receptor-Expressing T Cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. REV."},{"key":"B14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/hum.2015.054","article-title":"CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma","volume":"26","author":"Enblad","year":"2015","journal-title":"Hum. Gene. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/joim.12020","article-title":"Genetically Engineered T Cells for the Treatment of Cancer","volume":"273","author":"Essand","year":"2013","journal-title":"J. Intern. Med."},{"volume-title":"FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma","year":"2021","key":"B16"},{"volume-title":"FDA Approves Tisagenlecleucel for B-Cell ALL and MCL and Tocilizumab for Cytokine Release Syndrome","year":"2017","key":"B17"},{"key":"B18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fonc.2018.00453","article-title":"CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors","volume":"8","author":"Filley","year":"2018","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/cji.0000000000000169","article-title":"CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J. Immunother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine Release Syndrome with Novel Therapeutics for Acute Lymphoblastic Leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"B22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/nejmoa1215134","article-title":"Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone Cytokine in Health and Disease","volume":"16","author":"Hunter","year":"2015","journal-title":"NAT. Immounl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric Receptors with 4-1BB Signaling Capacity Provoke Potent Cytotoxicity against Acute Lymphoblastic Leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cbi.2007.11.005","article-title":"Dithiocarbamates and Viral IL-10 Collaborate in the Immortalization and Evasion of Immune Response in EBV-Infected Human B Lymphocytes","volume":"172","author":"Irons","year":"2008","journal-title":"Chemico-Biological Interactions"},{"key":"B28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/jco.2014.56.2025","article-title":"Chemotherapy-refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666x.2019.1629904","article-title":"Tocilizumab for the Treatment of Chimeric Antigen Receptor T Cell-Induced Cytokine Release Syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/moh.0000000000000548","article-title":"Mechanisms of Failure of Chimeric Antigen Receptor T-Cell Therapy","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.158.2.604","article-title":"The EBV IL-10 Homologue Is a Selective Agonist with Impaired Binding to the IL-10 Receptor","volume":"158","author":"Liu","year":"1997","journal-title":"J. Immunol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.5604\/01.3001.0010.3849","article-title":"Immune Disorders in Sepsis and Their Treatment as a Significant Problem of Modern Intensive Care","volume":"71","author":"Lysenko","year":"2017","journal-title":"Postepy Hig Med. Dosw (Online)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/jci123791","article-title":"Neoantigen Screening Identifies Broad TP53 Mutant Immunogenicity in Patients with Epithelial Cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev.immunol.021908.132532","article-title":"Alternative Activation of Macrophages: an Immunologic Functional Perspective","volume":"27","author":"Martinez","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.ccr-10-2616","article-title":"Inhibition of SRC Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors","volume":"17","author":"Montero","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/itt.s202015","article-title":"Cytokine Release Syndrome: Current Perspectives","author":"Murthy","year":"2019","journal-title":"Itt"},{"key":"B39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","article-title":"Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab","author":"Nishimoto","year":"2008","journal-title":"Handb Exp. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-Cell Therapeutics for Hematologic Malignancies: Interpreting Clinical Outcomes to Date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of Cytokine Release Syndrome Associated with the CAR T Cell Therapy Tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A Chimeric T Cell Antigen Receptor that Augments Cytokine Release and Supports Clonal Expansion of Primary Human T Cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.ccr-15-1527","article-title":"The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1038\/onc.2008.75","article-title":"Epstein-Barr Virus-Encoded Small RNA Induces IL-10 through RIG-I-Mediated IRF-3 Signaling","volume":"27","author":"Samanta","year":"2008","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T Cell-Encoded CD80 and 4-1BBL Induce Auto- and Transcostimulation, Resulting in Potent Tumor Rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic Implications of IL-6 Blockade for Cytokine Storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.cd-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010125","article-title":"Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment","volume":"12","author":"Titov","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity Related to CAR-T Cell Therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.815679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:01:47Z","timestamp":1674507707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.815679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":52,"alternative-id":["10.3389\/fgene.2021.815679"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.815679","relation":{},"ISSN":["1664-8021"],"issn-type":[{"type":"electronic","value":"1664-8021"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"article-number":"815679"}}